These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 9449910)
1. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Krueger GG; Drake LA; Elias PM; Lowe NJ; Guzzo C; Weinstein GD; Lew-Kaya DA; Lue JC; Sefton J; Chandraratna RA Arch Dermatol; 1998 Jan; 134(1):57-60. PubMed ID: 9449910 [TBL] [Abstract][Full Text] [Related]
2. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Guenther LC; Poulin YP; Pariser DM Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233 [TBL] [Abstract][Full Text] [Related]
3. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. Lebwohl M; Ast E; Callen JP; Cullen SI; Hong SR; Kulp-Shorten CL; Lowe NJ; Phillips TJ; Rosen T; Wolf DI; Quell JM; Sefton J; Lue JC; Gibson JR; Chandraratna RA J Am Acad Dermatol; 1998 May; 38(5 Pt 1):705-11. PubMed ID: 9591815 [TBL] [Abstract][Full Text] [Related]
4. Tazarotene gel: efficacy and safety in plaque psoriasis. Weinstein GD J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554 [TBL] [Abstract][Full Text] [Related]
5. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614 [TBL] [Abstract][Full Text] [Related]
6. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Weinstein GD; Krueger GG; Lowe NJ; Duvic M; Friedman DJ; Jegasothy BV; Jorizzo JL; Shmunes E; Tschen EH; Lew-Kaya DA; Lue JC; Sefton J; Gibson JR; Chandraratna RA J Am Acad Dermatol; 1997 Jul; 37(1):85-92. PubMed ID: 9216528 [TBL] [Abstract][Full Text] [Related]
7. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064 [TBL] [Abstract][Full Text] [Related]
8. Clinical safety of tazarotene in the treatment of plaque psoriasis. Marks R J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S25-32. PubMed ID: 9270553 [TBL] [Abstract][Full Text] [Related]
9. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS; J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506 [TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. Angelo JS; Kar BR; Thomas J Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037 [TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne. Leyden JJ Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714 [TBL] [Abstract][Full Text] [Related]
12. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Koo J; Behnam SE; Behnam SM Expert Opin Pharmacother; 2003 Dec; 4(12):2347-54. PubMed ID: 14640932 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials. Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780 [TBL] [Abstract][Full Text] [Related]
14. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409 [TBL] [Abstract][Full Text] [Related]
15. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Kaur I; Dogra S; Jain R; Kumar B Indian J Dermatol Venereol Leprol; 2008; 74(5):471-4. PubMed ID: 19052406 [TBL] [Abstract][Full Text] [Related]
16. Is switching retinoids a sound strategy for the treatment of acne vulgaris? Gold LS; Colón LE; Johnson LA; Gottschalk RW J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s11-7. PubMed ID: 18575221 [TBL] [Abstract][Full Text] [Related]
17. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Poulin YP Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595 [TBL] [Abstract][Full Text] [Related]
18. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066 [TBL] [Abstract][Full Text] [Related]
19. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy. J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713 [TBL] [Abstract][Full Text] [Related]
20. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. Bowman PH; Maloney JE; Koo JY J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]